Hologic, Inc. (NASDAQ:HOLX) Holdings Boosted by BDF Gestion

BDF Gestion grew its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 143.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 54,312 shares of the medical equipment provider's stock after buying an additional 32,000 shares during the quarter. BDF Gestion's holdings in Hologic were worth $3,355,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management purchased a new stake in shares of Hologic in the 1st quarter worth about $99,000. Exchange Traded Concepts LLC lifted its stake in Hologic by 21.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 25,303 shares of the medical equipment provider's stock valued at $1,563,000 after buying an additional 4,539 shares in the last quarter. Azzad Asset Management Inc. ADV purchased a new position in Hologic during the first quarter worth $1,790,000. NorthCrest Asset Manangement LLC lifted its position in shares of Hologic by 5.3% in the first quarter. NorthCrest Asset Manangement LLC now owns 6,727 shares of the medical equipment provider's stock valued at $416,000 after acquiring an additional 337 shares in the last quarter. Finally, CX Institutional purchased a new stake in shares of Hologic during the first quarter worth about $196,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOLX has been the subject of several recent analyst reports. Royal Bank Of Canada lowered their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Evercore ISI dropped their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Stephens decreased their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Twelve analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus target price of $77.42.

Insider Activity

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.88% of the company's stock.

Hologic Stock Down 0.3%

Shares of Hologic stock traded down $0.17 during trading on Thursday, reaching $63.97. The company had a trading volume of 3,239,812 shares, compared to its average volume of 2,330,435. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The firm's fifty day moving average is $59.03 and its 200-day moving average is $64.64. The company has a market cap of $14.26 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 2.35 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the business posted $1.03 EPS. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.